Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

@article{Citrome2013LevomilnacipranFM,
  title={Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?},
  author={Leslie Citrome},
  journal={International Journal of Clinical Practice},
  year={2013},
  volume={67}
}
  • L. Citrome
  • Published 1 November 2013
  • Psychology, Biology
  • International Journal of Clinical Practice
To describe the efficacy and safety of levomilnacipran (extended‐release capsules) for the treatment of major depressive disorder (MDD). 

Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

  • L. Citrome
  • Psychology
    International journal of clinical practice
  • 2014
The efficacy and safety of vortioxetine for the treatment of major depressive disorder (MDD) are described and the drug is described as safe and effective.

Levomilnacipran (Fetzima) for Major Depressive Disorder.

Levomilnacipran should not be used in patients with mild to moderate depression until studies have proven its effectiveness. It is somewhat effective in patients with moderate to severe depression.

Vilazodone: A landmark antidepressant approval or another "me-too" drug?

Vilazodone is a novel antidepressant which is indicated for the treatment of major depressive disorder (MDD) in adult patients. This article reviews the pharmacodynamics and pharmacokinetics of

Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder

Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder and their applications in clinical practice.

Vilazodone (viibryd) for the treatment of depression.

The available evidence does not support the routine use of vilazodone in the treatment of depression and it is significantly more expensive than generic alternatives and is no more effective than selective serotonin reuptake inhibitors or tricyclic antidepressants.

Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature

Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning, and there is no evidence as yet that vortioxidant is more clinically effective than other types of antidepressants.

Novel and Investigational Drugs in Depression

This article will highlight new psychopharmacological agents and investigational directions which may show promise in achieving better outcomes and symptom relief for those suffering from depression.

The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review

Preliminary evidence suggests that levomilnacipran ER may be effective in improving not only depressive symptoms but also symptoms related to functioning (social life, work, and family life) in relation to currently available antidepressants including other SNRIs.

Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

The current review comprehensively describes the development ofTRIs and discusses the importance of evaluation of in vivo transporter occupancy of TRIs, which should correlate with efficacy in humans.
...

References

SHOWING 1-10 OF 109 REFERENCES

Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

  • L. Citrome
  • Psychology, Medicine
    International journal of clinical practice
  • 2012
The efficacy and safety of vilazodone for the treatment of major depressive disorder are described and the drug is shown to be safe and effective.

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second‐generation antipsychotic

  • L. Citrome
  • Medicine, Psychology
    International journal of clinical practice
  • 2010
Objective:  To describe the contents of a Drug Approval Package and to describe the efficacy and safety of iloperidone for the treatment of schizophrenia.

The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder

Vilazodone 40 mg/day resulted in clinically meaningful, statistically significant improvement in MDD symptoms in two placebo-controlled, 8-week studies and was consistent for the majority of demographic and MDD characteristic subgroups.

Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study

No new or inconsistent safety/tolerability findings were discovered during longer-term evaluation of levomilnacipran extended-release ER, and vital sign changes occurred early and remained relatively stable.

Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat

The NNT for several measures of efficacy including remission consistently demonstrated the treatment benefits of duloxetine as well as of fluoxettine and paroxetines compared with placebo.

Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Vilazodone is effective for the treatment of MDD in adults, with symptom relief starting at 1 week, and is well tolerated at a dose of 40 mg/day, according to the intention-to-treat sample.

Choosing a second generation antidepressant for treatment of major depressive disorder

Patients should be involved in decision because drugs have similar efficacy but side effect profiles differ, according to the World Health Organization.

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.

Levomilnacipran ER at doses of 40 mg/ day and 80 mg/day demonstrated efficacy on symptomatic and functional measures of MDD and was generally well tolerated in this patient population.
...